A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass
Open accessThe DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index; 86 of the 118 sources its claims cite were checked for support.
Abstract
Obesity in women over 65 represents a growing clinical challenge, particularly due to its association with increased risks of cardiovascular disease, osteoarthritis, frailty, sleep-breathing disorders, and sarcopenia. The prevalence of obesity in this demographic is compounded by age-related metabolic changes and declining physical activity. In this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide and tirzepatide, have emerged as promising pharmacological treatments for weight loss, showing substantial efficacy in reducing body weight and improving metabolic health. However, their use in older populations warrants careful consideration due to the potential risk of muscle loss, which may exacerbate sarcopenia and frailty. This review synthesizes current evidence on the efficacy of GLP-1 RAs for weight loss in older women, exploring both the metabolic benefits and potential risks, particularly with regard to muscle mass preservation. We discuss the mechanisms behind muscle loss associated with GLP-1 RAs, focusing on the balance between fat reduction and the preservation of lean body mass. In phase 3 trials, women aged ≥ 65 years achieved sustained weight loss of 10-20%, with consistent cardiometabolic improvements. Furthermore, we propose practical strategies to mitigate sarcopenia, including physical activity interventions, dietary modifications, and combination therapies aimed at maintaining muscle strength while promoting weight loss. By examining clinical trial data, real-world evidence, and physiological mechanisms, this narrative review aims to provide a comprehensive framework for personalized and safe therapeutic decision-making, addressing the unique needs of older women with obesity.
Overview
CoChat Summary
## TL;DR
This narrative review argues that GLP-1 receptor agonists, especially semaglutide and tirzepatide, can produce clinically meaningful weight loss and cardiometabolic improvement in women over 65, but a substantial fraction of weight loss may come from lean mass. The paper emphasizes geriatric screening and muscle-preserving strategies—resistance exercise, adequate protein intake, and ongoing functional monitoring—to reduce sarcopenia-related risks.
## Key findings
- In the review’s summary of phase 3 trials, women aged ≥65 years achieved sustained weight loss of 10–20%, with consistent cardiometabolic improvements.
- In STEP trials of semaglutide, women aged 65+ had average weight loss of 10–15%; the effect was slightly attenuated in those over 70 years.
- In SURMOUNT-1 and SURMOUNT-2 tirzepatide trials, mean body-weight reduction ranged from 15% to 21%, with effects sustained up to 72 weeks.
- Across trials, about 25–40% of total weight loss with GLP-1 RAs was attributed to lean mass loss; in the cited SEMALEAN study (106 patients, predominantly female), sarcopenic obesity prevalence fell from 49% to 33% after 12 months of semaglutide, despite an early lean-mass decline of about −3 kg.
## Methods
- Narrative review of GLP-1 receptor agonists for obesity in older women, with attention to efficacy, body composition, functional outcomes, and sarcopenia risk.
- Literature search used PubMed, Scopus, and Web of Science; publications from January 2015 to March 2025 were considered, and the final search was conducted on 15 March 2025.
- The authors included 62 articles in the final qualitative synthesis and stated that evidence was synthesized narratively because of heterogeneity across study designs and outcomes.
## Limitations
- The paper states that data on women over 75 years of age remains limited.
- It also notes that real-world applications must be interpreted cautiously because frail older adults may have cognitive impairments, mobility limitations, polypharmacy, injection difficulties, and poorer tolerance of appetite suppression.
- Evident from the text: this is a narrative review, so it does not provide a new pooled estimate or original patient-level analysis; its conclusions depend on heterogeneous studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
51 Valid · 10 Not valid · 17 Not checked · 14 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In other words, weight reduction was observed during active treatment, while post-discontinuation follow-up indicated relative weight stability after treatment cessation, rather than further weight loss or rebound.”
§ A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass > 4. Efficacy of GLP-1 Receptor Agonists in Women Aged > 65 Years > 4.1. Evidence from Randomized Controlled Trials
What the sources say
- Disputedcites [39] Garvey, 2022, Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial, Nat. Med. sourceExperimental — accuracy not yet measured
The Discussion attributes STEP 5’s relative weight stability between weeks 52 and 104 to continued semaglutide treatment, not to follow-up after cessation. It also states that the STEP 4 withdrawal trial and STEP 1 off-treatment extension showed weight regain after semaglutide discontinuation—the opposite of the claimed absence of rebound. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, caloric restriction, which is commonly recommended for weight loss, may lead to negative consequences in older individuals, such as further muscle depletion, malnutrition, and a decline in functional capacity [14].”
§ A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass > 1. Introduction
What the sources say
- Partly supportedcites [14] Volek, 2024, Nutritional Considerations During Major Weight Loss Therapy: Focus on Optimal Protein and a Low-Carbohydrate Dietary Pattern, Curr. Nutr. Rep. sourceExperimental — accuracy not yet measured
The Introduction (Purpose; page unavailable) warns that significant caloric restriction makes preserving muscle mass, micronutrient intake, and functionality important. The Dietary Protein section says energy deficits can accelerate protein degradation, and Low-Fat vs Low-Carbohydrate Diets says adequate micronutrient intake is challenging during restriction. These passages support the general risks, but do not establish that restriction causes malnutrition or functional decline specifically in older individuals. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Despite this attenuation, the improvements observed in metabolic parameters, such as HbA1c (glycated hemoglobin), blood pressure, and lipid profiles, were significant.”
§ A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass > 4. Efficacy of GLP-1 Receptor Agonists in Women Aged > 65 Years > 4.1. Evidence from Randomized Controlled Trials
What the sources say
- Partly supportedcites [35] Wilding, 2021, Once-weekly semaglutide in adults with overweight or obesity, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The Other Confirmatory and Supportive Secondary End Points section reports improvements in blood pressure, glycated hemoglobin, and fasting lipids with semaglutide; Table 2 reports a significant systolic blood-pressure difference and estimates favoring semaglutide for the other measures. These are results for the overall trial population, not specifically older women. The cited passages do not establish that the improvements persisted despite attenuated weight loss in that group. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [36] Davies, 2021, Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes (STEP 2), Lancet source
- Partly supportedcites [37] Wadden, 2021, Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial, JAMA sourceExperimental — accuracy not yet measured
Table 2 (page not provided) reports significant improvements versus placebo in HbA1c, systolic and diastolic blood pressure, and several lipid measures in the overall STEP 3 population; the HDL difference was not significant. The paper does not establish these results specifically for older women or show that they persisted despite attenuated weight loss in that group. (LLM, conf=0.88)
- Partly supportedcites [38] Rubino, 2021, Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial, JAMA sourceExperimental — accuracy not yet measured
Table 2 reports significant differences between continued semaglutide and placebo for HbA1c and systolic blood pressure; the Confirmatory and Supportive Secondary End Points section also reports improved lipid profiles. The Participants section describes adults with overweight or obesity, not an older-women subgroup, and Table 2 shows continued weight loss with semaglutide rather than attenuation. The cited trial therefore supports the metabolic findings, but not their stated population and weight-loss context. (LLM, conf=0.86)
- Partly supportedcites [39] Garvey, 2022, Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial, Nat. Med. sourceExperimental — accuracy not yet measured
The Results (Efficacy endpoint results for the treatment policy estimand; page not provided) report improvements in HbA1c, blood pressure and several lipid measures with semaglutide versus placebo. They do not establish these effects specifically in older women, and the Discussion describes weight loss plateauing and being maintained rather than attenuating. Systolic blood pressure was a confirmatory endpoint; HbA1c and lipids were supportive endpoints, and the reported intervals do not show improvement for every lipid measure. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mitochondrial dysfunction leads to decreased energy production in muscle cells, impairing their ability to maintain mass and function [7,8].”
§ A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass > 1. Introduction
What the sources say
- Partly supportedcites [7] Xu, 2025, Reactive oxygen species in the pathogenesis of sarcopenia, Free Radic. Biol. Med. sourceExperimental — accuracy not yet measured
The “Mitochondrial function and ROS generation” section (page unavailable) links mitochondrial dysfunction in skeletal muscle to altered energetics and reports reduced respiratory-complex activity and oxidative phosphorylation in sarcopenia. The “Impact of oxidative stress and lipid hydroperoxides on muscle proteostasis” section links mitochondrial oxidative stress to loss of muscle mass. The copy does not establish the claim’s specific causal chain that decreased energy production impairs maintenance of muscle mass and function; it emphasizes ROS and proteolysis instead. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [8] Gambini, 2024, Diet and exercise in frailty and sarcopenia: Molecular aspects, Mol. Asp. Med. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“GLP-1 RAs, including semaglutide and tirzepatide, have demonstrated significant efficacy in promoting weight loss and improving metabolic health in younger populations [15].”
§ A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass > 1. Introduction
What the sources say
- Partly supportedcites [15] Kokkorakis, 2025, Emerging pharmacotherapies for obesity: A systematic review, Pharmacol. Rev. sourceExperimental — accuracy not yet measured
The Discussion reports substantial weight loss with semaglutide, and the review describes tirzepatide as having weight-reducing and glucose-lowering effects. However, the Eligibility criteria limit the reviewed trials to adults and explicitly exclude children and adolescents. The source therefore does not establish the claimed efficacy in younger populations. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
55 more claims · 33 with their cited sources checked
Create a free account to see all 92 claims and to verify the 7 references still open.
- Probably not a substantial claim. 3
- It may state two separate claims as one. 29
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass > 2. Methods
“A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science (First access to data bases in 10 July 2025, last in 30 December 2025); the literature search covered publications from January 2015 to March 2025, with the final search conducted on 15 March 2025”
§ A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass > 2. Methods
“the final search conducted on 15 March 2025, in order to capture the most recent decade of evidence on GLP-1 receptor agonists and body composition outcomes in older adults.”
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 2×
“In these situations, EWGSOP2 advises using the SARC-F questionnaire to gather patients’ self-reported information on typical sarcopenia-related issues [59].”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 2×
“Two major trial programs, the STEP program for semaglutide [35–39] and the SURMOUNT trials [40–43] for tirzepatide, offer critical insights into the benefits of these therapies in older populations.”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“Similarly, the SURMOUNT-1 [40] and 2 [41] trials, which evaluated the effects of tirzepatide, revealed even greater weight loss efficacy, with mean reductions in body weight ranging from 15% to 21%.”
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
The Global Burden of Cardiovascular Diseases and Risk
Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V., & Roth, G. A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.005 · Cited by 2,217
Sarcopenia: Aging-Related Loss of Muscle Mass and Function
Larsson, L., Degens, H., Li, M., Salviati, L., Lee, Y. I., Thompson, W., Kirkland, J. L., & Sandri, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00061.2017 · Cited by 1,797 · cited 1×
“This decline in muscle mass, combined with the accumulation of visceral fat, creates a dangerous interplay that exacerbates frailty and reduces functional capacity [6,7].”
World guidelines for falls prevention and management for older adults: a global initiative
Montero-Odasso, M., van der Velde, N., Martin, F. C., Petrovic, M., Tan, M. P., Ryg, J., Aguilar-Navarro, S., Alexander, N. B., Becker, C., Blain, H., et al. (2022) · Age and Ageing · doi:10.1093/ageing/afac205 · Cited by 1,756 · cited 1×
“This may involve integrating resistance training and physical rehabilitation programs alongside pharmacologic interventions to optimize outcomes [21].”
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382 · cited 3×
“Weight loss in older women must be carefully managed to avoid the unintended consequence of sarcopenia, a condition that further exacerbates frailty and increases the risk of falls, disability, and premature mortality [19].”
Cited by
Simancas‐Racines, D., Campuzano-Donoso, M., Rossetti, G., Cobellis, L., Pilone, V., Fascì-Spurio, F., Gavilanes, D. J., Soria, C., Reytor-González, C., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100290 · Cited by 3
“Several studies have shown that a proportion of weight loss, often estimated at 20 – 40%, may derive from lean body mass, particularly when protein intake and resistance exercise are not maintained [108,236,237].”
Ortiz‐Prado, E., Vasconez-Gonzalez, J., Izquierdo‐Condoy, J. S., & López-Jaramillo, P. A. (2026) · doi:10.2196/preprints.99738
Pendrey, A., Sierra, J. A. R., Lobo, F. A. A., Herrera, E. J. R., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03702-4
“GLP-1 RAs, such as semaglutide, liraglutide, and tirzepatide, have emerged as novel treatment options for diabetes and obesity by improving insulin sensitivity and modulating inflammation, respectively [41].”
Liver muscle bone axis in metabolic dysfunction-associated steatotic liver disease
Binhua, L., Zhang, Y., Can, Z. H. O. U., Cao, H., & Zeng, J. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.113 · Cited by 1
Narla, S., & Narla, R. R. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.07.030 · Cited by 1
Metadata
- Authors
- Moscucci, F., Baratta, F., Pastori, D., Menichelli, D., Mattioli, A. V., Gallina, S., Lospinuso, I., Sciomer, S., Piccirillo, G., & Desideri, G.
- Affiliations
- University of L'Aquila (IT)
- Policlinico Umberto I (IT)
- Department of Medical and Cardiovascular Sciences, University of Rome “Sapienza”, 00161 Rome, Italy
- Sapienza University of Rome (IT)
- University of Bologna (IT)
- University of Chieti-Pescara (IT)
- Corresponding author
- Moscucci, Federica
- Baratta, Francesco
- ORCID
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2026-02-14
- Volume
- 18
- Issue
- 4
- Pages
- 632
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC12943638
- OpenAlex
- W7128924619
- Semantic Scholar
- f6d0f8881ca2e23645760aa110d4de96f2d4d410
- Cited by
- 11
- References
- 76
- Citations by year
- 2026: 11
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, weight loss, lean mass preservation, sarcopenia, frailty, semaglutide, tirzepatide, muscle mass loss, cardiometabolic risk, physical activity interventions, dietary change, combination therapy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Aged, Body Composition, Glucagon-Like Peptides, Female, Humans, Obesity, Weight Loss, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass. https://app.cochat.ai/papers/10.3390/nu18040632
- The paper
- Moscucci, F., Baratta, F., Pastori, D., Menichelli, D., Mattioli, A. V., Gallina, S., Lospinuso, I., Sciomer, S., Piccirillo, G., & Desideri, G. (2026). A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass. Nutrients. https://doi.org/10.3390/nu18040632
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.